Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
This book answers the questions about the process and costs of pharmaceutical R & D in a compelling narrative focused on the discovery and development of important new medicines. It gives an insider's account of the pharmaceutical industry drug discovery process, the very real costs of misperceptions about the industry, the high stakes--both economic and scientific--of developing drugs, the triumphs that come when new compounds reach the market and save lives, and the despair that follows when new compounds fail. In the book, John LaMattina, former president of Pfizer Global Research and…mehr
This book answers the questions about the process and costs of pharmaceutical R & D in a compelling narrative focused on the discovery and development of important new medicines. It gives an insider's account of the pharmaceutical industry drug discovery process, the very real costs of misperceptions about the industry, the high stakes--both economic and scientific--of developing drugs, the triumphs that come when new compounds reach the market and save lives, and the despair that follows when new compounds fail. In the book, John LaMattina, former president of Pfizer Global Research and Development, weaves themes critical to a vital drug discovery environment in the context. This is a story that Dr. LaMattina is uniquely qualified to tell.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in D ausgeliefert werden.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Autorenporträt
John L. LaMattina, PhD, retired as president of Pfizer Global Research and Development in 2007 where he managed more than 13,000 scientists and support professionals in the United States, Europe, and Asia. Dr. LaMattina has received numerous awards including an Honorary Doctor of Science degree from the University of New Hampshire.
Inhaltsangabe
ACKNOWLEDGMENTS ix INTRODUCTION xi PART I A MATTER OF THE HEART 1 CHAPTER 1 CHOLESTEROL DRUGS ARE UNNECESSARY 3 CHAPTER 2 INDUSTRY IS MORE INTERESTED IN "ME-TOO" DRUGS THAN IN INNOVATION 13 CHAPTER 3 IT TAKES INDUSTRY TOO LONG TO DISCOVER NEW DRUGS 23 PART II THE ROLE OF PHARMACEUTICAL R&D IN HEALTH CARE 39 CHAPTER 4 DRUGS ARE DISCOVERED BY ACADEMIA 41 CHAPTER 5 NEW MEDICINES ADD COSTS BUT LITTLE BENEFIT 50 CHAPTER 6 BIG PHARMA HAS FAILED AND SHOULD LEARN FROM BIOTECH SUCCESS 59 PART III THE PROFIT MOTIVE 69 CHAPTER 7 THE INDUSTRY INVENTS DISEASES 71 CHAPTER 8 NEW DRUGS ARE LESS SAFE THAN TRADITIONAL MEDICINES 79 CHAPTER 9 INDUSTRY SPENDS MORE ON ADVERTISING THAN ON R&D 91 CHAPTER 10 INDUSTRY DOES NOT CARE ABOUT DISEASES OF THE DEVELOPING WORLD 100 PART IV THE FUTURE 109 CHAPTER 11 BIG PHARMA'S DAY HAS PASSED 111 CHAPTER 12 FINAL REFLECTIONS 122 REFERENCES 124 INDEX 133
ACKNOWLEDGMENTS ix INTRODUCTION xi PART I A MATTER OF THE HEART 1 CHAPTER 1 CHOLESTEROL DRUGS ARE UNNECESSARY 3 CHAPTER 2 INDUSTRY IS MORE INTERESTED IN "ME-TOO" DRUGS THAN IN INNOVATION 13 CHAPTER 3 IT TAKES INDUSTRY TOO LONG TO DISCOVER NEW DRUGS 23 PART II THE ROLE OF PHARMACEUTICAL R&D IN HEALTH CARE 39 CHAPTER 4 DRUGS ARE DISCOVERED BY ACADEMIA 41 CHAPTER 5 NEW MEDICINES ADD COSTS BUT LITTLE BENEFIT 50 CHAPTER 6 BIG PHARMA HAS FAILED AND SHOULD LEARN FROM BIOTECH SUCCESS 59 PART III THE PROFIT MOTIVE 69 CHAPTER 7 THE INDUSTRY INVENTS DISEASES 71 CHAPTER 8 NEW DRUGS ARE LESS SAFE THAN TRADITIONAL MEDICINES 79 CHAPTER 9 INDUSTRY SPENDS MORE ON ADVERTISING THAN ON R&D 91 CHAPTER 10 INDUSTRY DOES NOT CARE ABOUT DISEASES OF THE DEVELOPING WORLD 100 PART IV THE FUTURE 109 CHAPTER 11 BIG PHARMA'S DAY HAS PASSED 111 CHAPTER 12 FINAL REFLECTIONS 122 REFERENCES 124 INDEX 133
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826